What is PanOptica?
PanOptica operates at the intersection of biotechnology and ophthalmology, focusing on the identification and development of therapeutic candidates that address unmet medical needs. Founded by industry veterans Paul Chaney and Dr. Martin Wax, the company utilizes a sophisticated model of asset translation, repurposing scientific discoveries from diverse disease areas for ocular applications. This strategic focus allows the firm to mitigate early-stage development risks while maintaining a robust portfolio of high-potential candidates. By prioritizing clinical proof of concept, PanOptica distinguishes itself from traditional drug discovery firms, emphasizing translational efficiency and scientific rigor in its pursuit of next-generation eye care treatments.
How much funding has PanOptica raised?
PanOptica has raised a total of $75M across 2 funding rounds:
Series A
$30M
Series B
$45M
Series A (2011): $30M with participation from Third Rock Ventures and SV Life Sciences
Series B (2014): $45M led by Novo Ventures, Third Rock Ventures, and SV Life Sciences
Key Investors in PanOptica
Third Rock Ventures
A healthcare venture firm focused on disruptive science and medicine, dedicated to launching companies that make a dramatic difference in patient lives.
SV Health Investors
A specialist investment firm backing innovative health care and life science companies, providing capital and sector expertise from early growth through scale.
Novo Ventures
The investment arm of the Novo Nordisk Foundation, focusing on long-term value creation within the global life sciences and biotechnology sectors.
What's next for PanOptica?
With the capital secured through its major enterprise-level funding, PanOptica is well-positioned to accelerate its clinical development programs. The company's roadmap likely involves advancing its lead candidates through rigorous human trials, a critical phase for validating its translational research model. As the firm matures, the focus will shift toward optimizing its operational infrastructure and potentially exploring strategic partnerships to facilitate the commercialization of its pipeline. The continued support from its investor base suggests a long-term commitment to building a sustainable, high-impact biopharmaceutical entity capable of delivering transformative outcomes for patients suffering from complex ophthalmological conditions.
See full PanOptica company page
